Logo image of CRBP2.PA

CRCAM BRIE PIC2-CCI (CRBP2.PA) Stock Fundamental Analysis

EPA:CRBP2 - Euronext Paris - Matif - FR0010483768 - Common Stock - Currency: EUR

22.1  +0.1 (+0.45%)

Fundamental Rating

2

Taking everything into account, CRBP2 scores 2 out of 10 in our fundamental rating. CRBP2 was compared to 93 industry peers in the Banks industry. CRBP2 may be in some trouble as it scores bad on both profitability and health. CRBP2 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CRBP2 had positive earnings in the past year.
In the past year CRBP2 has reported a negative cash flow from operations.
CRBP2 had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CRBP2 reported negative operating cash flow in multiple years.
CRBP2.PA Yearly Net Income VS EBIT VS OCF VS FCFCRBP2.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B -1B 1.5B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.49%, CRBP2 is doing worse than 62.37% of the companies in the same industry.
CRBP2 has a worse Return On Equity (3.96%) than 73.12% of its industry peers.
Industry RankSector Rank
ROA 0.49%
ROE 3.96%
ROIC N/A
ROA(3y)0.49%
ROA(5y)0.48%
ROE(3y)4.24%
ROE(5y)4.06%
ROIC(3y)N/A
ROIC(5y)N/A
CRBP2.PA Yearly ROA, ROE, ROICCRBP2.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

1.3 Margins

CRBP2 has a Profit Margin of 24.09%. This is in the better half of the industry: CRBP2 outperforms 62.37% of its industry peers.
CRBP2's Profit Margin has declined in the last couple of years.
The Operating Margin and Gross Margin are not available for CRBP2 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 24.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y5.73%
PM growth 5Y-3.62%
GM growth 3YN/A
GM growth 5YN/A
CRBP2.PA Yearly Profit, Operating, Gross MarginsCRBP2.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15 20 25

More info and screens

2

2. Health

2.1 Basic Checks

CRBP2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRBP2 has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRBP2 has more shares outstanding
Compared to 1 year ago, CRBP2 has an improved debt to assets ratio.
CRBP2.PA Yearly Shares OutstandingCRBP2.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CRBP2.PA Yearly Total Debt VS Total AssetsCRBP2.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

2.2 Solvency

CRBP2 has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.08, CRBP2 belongs to the best of the industry, outperforming 91.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC5.54%
CRBP2.PA Yearly LT Debt VS Equity VS FCFCRBP2.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B 4B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRBP2.PA Yearly Current Assets VS Current LiabilitesCRBP2.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.62% over the past year.
The Earnings Per Share has been growing slightly by 0.64% on average over the past years.
The Revenue has been growing slightly by 4.32% in the past year.
The Revenue has been growing slightly by 4.77% on average over the past years.
EPS 1Y (TTM)18.62%
EPS 3Y15.1%
EPS 5Y0.64%
EPS Q2Q%4.74%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y9.35%
Revenue growth 5Y4.77%
Sales Q2Q%2.28%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP2.PA Yearly Revenue VS EstimatesCRBP2.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M
CRBP2.PA Yearly EPS VS EstimatesCRBP2.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.92, which indicates a rather cheap valuation of CRBP2.
Compared to the rest of the industry, the Price/Earnings ratio of CRBP2 indicates a rather cheap valuation: CRBP2 is cheaper than 88.17% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CRBP2 to the average of the S&P500 Index (29.35), we can say CRBP2 is valued rather cheaply.
Industry RankSector Rank
PE 5.92
Fwd PE N/A
CRBP2.PA Price Earnings VS Forward Price EarningsCRBP2.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP2.PA Per share dataCRBP2.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)9.21
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.00%, CRBP2 is a good candidate for dividend investing.
CRBP2's Dividend Yield is comparable with the industry average which is at 5.02.
CRBP2's Dividend Yield is rather good when compared to the S&P500 average which is at 2.33.
Industry RankSector Rank
Dividend Yield 5%

5.2 History

The dividend of CRBP2 decreases each year by -0.76%.
Dividend Growth(5Y)-0.76%
Div Incr Years3
Div Non Decr Years3
CRBP2.PA Yearly Dividends per shareCRBP2.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
CRBP2.PA Yearly Income VS Free CF VS DividendCRBP2.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B -1B 1.5B

More info and screens

CRCAM BRIE PIC2-CCI

EPA:CRBP2 (3/7/2025, 7:00:00 PM)

22.1

+0.1 (+0.45%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)01-28 2025-01-28
Earnings (Next)04-28 2025-04-28
Inst Owners4.3%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap353.82M
Analysts83.64
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5%
Yearly Dividend0.63
Dividend Growth(5Y)-0.76%
DPN/A
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.92
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)3.73
EY16.88%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-82.2
FCFYN/A
OCF(TTM)-81.2
OCFYN/A
SpS53.08
BVpS322.74
TBVpS322.72
PEG (NY)N/A
PEG (5Y)9.21
Profitability
Industry RankSector Rank
ROA 0.49%
ROE 3.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 24.09%
GM N/A
FCFM N/A
ROA(3y)0.49%
ROA(5y)0.48%
ROE(3y)4.24%
ROE(5y)4.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y5.73%
PM growth 5Y-3.62%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.33%
Cap/Sales 1.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC5.54%
ROIC/WACCN/A
Cap/Depr(3y)76.58%
Cap/Depr(5y)109.94%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.62%
EPS 3Y15.1%
EPS 5Y0.64%
EPS Q2Q%4.74%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y9.35%
Revenue growth 5Y4.77%
Sales Q2Q%2.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-157.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-156.1%
OCF growth 3YN/A
OCF growth 5YN/A